Molecular Pathways: Fibroblast Growth Factor Signaling: A New Therapeutic Opportunity in Cancer
Molecular Pathways: Fibroblast Growth Factor Signaling: A New Therapeutic Opportunity in Cancer
复制标题
DOI：
10.1158/1078-0432.ccr-11-0699
复制
发表时间：
2012-04-01
影响因子：
11.5
通讯作者：
Smith, Paul D.
中科院分区：
文献类型：
--
作者：
Brooks, A. Nigel;Kilgour, Elaine;Smith, Paul D.
成纤维细胞生长因子/成纤维细胞生长因子受体（FGF/FGFR）信号轴在正常器官，血管和骨骼发育中起重要作用。在许多肿瘤环境中观察到了通过遗传修饰或受体（或其配体）过表达对FGFR信号传导的管制，而FGF/FGFR轴也在驱动肿瘤血管生成中起关键作用。越来越多的临床前数据表明，抑制FGFR信号传导会导致体外和体内的抗增殖和/或促凋亡作用，从而确认FGF/FGFR轴的有效性是潜在的治疗靶标。过去，我们无法开发FGFR选择剂的治疗方法的开发阻碍了针对该轴的治疗方法。随着许多新模式的出现，用于有选择地抑制FGF/FGFR信号，我们现在处于独特的位置，可以在临床上测试和验证临床的许多假设。 Clin Cancer res; 18（7）; 1855-62。（c）2012 AACR。
The fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) signaling axis plays an important role in normal organ, vascular, and skeletal development. Deregulation of FGFR signaling through genetic modification or overexpression of the receptors (or their ligands) has been observed in numerous tumor settings, whereas the FGF/FGFR axis also plays a key role in driving tumor angiogenesis. A growing body of preclinical data shows that inhibition of FGFR signaling can result in antiproliferative and/or proapoptotic effects, both in vitro and in vivo, thus confirming the validity of the FGF/FGFR axis as a potential therapeutic target. In the past, development of therapeutic approaches to target this axis has been hampered by our inability to develop FGFR-selective agents. With the advent of a number of new modalities for selectively inhibiting FGF/FGFR signaling, we are now in a unique position to test and validate clinically the many hypotheses that have been generated preclinically. Clin Cancer Res; 18(7); 1855- 62. (C) 2012 AACR.